Publications by authors named "Michael D Altman"

Claim this Profile
F
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose Projections.
H Marie Loughran, Kathy M Schirripa, Anthony J Roecker, Michael J Breslin, Ling Tong, Michael D Altman

ACS Med Chem Lett· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease.
Anthony J Roecker, Kathy M Schirripa, H Marie Loughran, Ling Tong, Tao Liang, Michael D Altman

ACS Med Chem Lett· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of unprecedented 9- and 10-membered cyclonucleosides with PRMT5 inhibitory activity.
Shuhei Kawamura, Rachel L Palte, Hai-Young Kim, Josep Saurí, Christopher Sondey, Michael D Altman

Bioorg Med Chem· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
Wonsuk Chang, Michael D Altman, Charles A Lesburg, Samanthi A Perera, Jennifer A Piesvaux

J Med Chem· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A kinase-cGAS cascade to synthesize a therapeutic STING activator.
John A McIntosh, Zhijian Liu, Brian M Andresen, Nastaran Salehi Marzijarani, Jeffrey C Moore, Michael D Altman

Nature· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer.
Vladimir Simov, Michael D Altman, Elisabetta Bianchi, Sonia DelRizzo, Edward N DiNunzio

Eur J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of : an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction.
Michael H Reutershan, Michelle R Machacek, Michael D Altman, Stephane Bogen, Mingmei Cai

J Med Chem· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a new series of PI3K-δ inhibitors from Virtual Screening.
Xavier Fradera, Qiaolin Deng, Abdelganhi Achab, Yudith Garcia, Solomon D Kattar, Michael D Altman

Bioorg Med Chem Lett· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators.
Joey L Methot, Hua Zhou, Meredeth A McGowan, Neville John Anthony, Matthew Christopher, Michael D Altman

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).
Rachel L Palte, Sebastian E Schneider, Michael D Altman, Robert P Hayes, Shuhei Kawamura

ACS Med Chem Lett· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow" [Bioorg. Med. Chem. Lett. 29 (2019) 2575-2580].
Xavier Fradera, Joey L Methot, Abdelghani Achab, Matthew Christopher, Michael D Altman

Bioorg Med Chem Lett· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An orally available non-nucleotide STING agonist with antitumor activity.
Bo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, Jeremy P Presland, Gottfried K Schroeder, Michael D Altman

Science· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow.
Xavier Fradera, Joey L Methot, Abdelghani Achab, Matthew Christopher, Michael D Altman

Bioorg Med Chem Lett· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING.
Tony Siu, Michael D Altman, Gretchen A Baltus, Matthew Childers, J Michael Ellis

ACS Med Chem Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpretation of Metabolic Stability Studies for Racemic Mixtures.
James A Baker, Michael D Altman, Iain J Martin

ACS Med Chem Lett· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategy for Extending Half-life in Drug Design and Its Significance.
Hakan Gunaydin, Michael D Altman, J Michael Ellis, Peter Fuller, Scott A Johnson

ACS Med Chem Lett· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
John P Santa Maria, Yumi Park, Lihu Yang, Nicholas Murgolo, Michael D Altman

ACS Chem Biol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
Graham F Smith, Michael D Altman, Brian Andresen, James Baker, Jason D Brubaker

Bioorg Med Chem Lett· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species.
Pierre Daublain, Kung-I Feng, Michael D Altman, Iain Martin, Suman Mukherjee

Mol Pharm· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors.
Jason D Katz, Andrew Haidle, Kaleen K Childers, Anna A Zabierek, James P Jewell, Michael D Altman

Bioorg Med Chem Lett· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.
Andrew M Haidle, Kaleen K Childers, Anna A Zabierek, Jason D Katz, James P Jewell, Michael D Altman

Bioorg Med Chem Lett· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization.
J Michael Ellis, Michael D Altman, Brandon Cash, Andrew M Haidle, Rachel L Kubiak

ACS Med Chem Lett· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context.
Bryan Severyn, Thi Nguyen, Michael D Altman, Lixia Li, Kumiko Nagashima

J Biomol Screen· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.
David L Sloman, Njamkou Noucti, Michael D Altman, Dapeng Chen, Andrea C Mislak

Bioorg Med Chem Lett· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications.
Jongwon Lim, Michael D Altman, James Baker, Jason D Brubaker, Hongmin Chen

Bioorg Med Chem Lett· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis